These Regulations may be cited as the Medical Devices (Consultation Requirements) (Fees) Regulations 1995 and shall come into force on 20th March 1995.

In these Regulations—

• “Annex II” and “Annex III” mean respectively Annex II and Annex III to the Directive;

• “approved manufacturer” in relation to a medicinal substance means a manufacturer who—

  1. (a)

     holds a manufacturing authorisation which permits him to manufacture that substance for inclusion in an authorised medicinal product; or

  2. (b)

     is permitted under the Directive to manufacture that substance for incorporation in a medical device in respect of which an EC examination certificate has been issued by a notified body which has consulted the competent body;

• “authorised medicinal product” means a medicinal product in respect of which there is—

  1. (a)
     a Community marketing authorisation granted by the European Commission under Council Regulation (EEC) No. 2309/932;
  2. (b)
     a United Kingdom marketing authorisation granted under the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 19943;
  3. (c)

     a product licence which is given effect as such a United Kingdom marketing authorisation by paragraph 1 of Schedule 6 to those Regulations; or

  4. (d)

     any other product licence, other than a product licence of right;

• “competent body” means the body which, in the United Kingdom, is the competent authority established in accordance with Council Directive 65/65/EEC4; “consultation” means a consultation required either by paragraph 4.3 of Annex II or by paragraph 5 of Annex III;
• “the Directive” means Council Directive 93/42/EEC5;

• “EC examination certificate” means either an EC design-examination certificate within the meaning of paragraph 4.3 of Annex II or an EC type-examination certificate within the meaning of paragraph 5 of Annex III;

• “fee” means a fee specified in, or determined under, regulation 3;

• “incorporates” means incorporates as an integral part;

• “manufacturing authorisation” has the same meaning as in Article 16 of Council Directive 75/319/EEC6;

• “medical device” has the same meaning as in Article 1.2(a) of the Directive;

• “medicinal substance” means a substance which, if used separately from a medical device, may be considered to be a medicinal product as defined in Article 1 of Council Directive 65/65/EEC;

• “new medicinal substance” means a medicinal substance which is not—

  1. (a)

     an authorised medicinal product for human use;

  2. (b)

     an ingredient or, as the case may be, the sole active ingredient of such a product; or

  3. (c)

     a substance which has been incorporated in a medical device in respect of which an EC examination certificate has been issued by a notified body which has consulted the competent body;

• “notified body” has the same meaning as in Article 16 of the Directive;

• “placed on the market” in relation to a medical device refers to the “placing on the market”, as defined in paragraph 2(h) of Article 1 of the Directive, of that device;

• “product licence” has the same meaning as in section 7 of the Medicines Act 19687;

• “product licence of right” means a product licence which is a licence of right within the meaning of section 25(4) of that Act;

• “put into service” in relation to a medical device refers to the “putting into service”, as defined in paragraph 2(i) of Article 1 of the Directive, of that device.

For the purposes of paragraph (3), the relevant period means the period of 5 years which starts on the first day on which the competent body was consulted in respect of the unsuccessful application in question or, if there has been more than one such application in any particular case, in respect of the first of them.

In these Regulations, unless the context requires otherwise, a reference to a numbered regulation is a reference to the regulation of these Regulations which is so numbered and a reference in a regulation to a numbered paragraph is a reference to the paragraph of that regulation which is so numbered.